Quick Facts

• Targeted Conditions: Management of common gastrointestinal roundworm, hookworm, and whipworm infections.
• Patient Population: Used for puppies and young dogs up to one year of age.

Drontal Pup Oral Suspension is a veterinary medicinal product that is indicated for the management of specific gastrointestinal parasite infections in puppies and young dogs. The product is used to address the presence of roundworms, specifically Toxocara canis and Toxascaris leonina.

Additionally, this formulation is associated with the removal of hookworms, including Ancylostoma caninum and Uncinaria stenocephala. It serves a role in the treatment protocol for the whipworm species, Trichuris vulpis. Through its intended use, the medication may assist in minimizing the effects of these nematode parasites in the canine patient population.

Treatment is typically initiated in young animals to support early parasite burden reduction.

Regulatory References

1. EMA therapeutic overview

Eligibility for Drontal Pup Oral Suspension

Drontal Pup Oral Suspension is a veterinary medicinal product whose use is strictly defined by regulatory eligibility criteria, primarily focusing on the patient's age and clinical status. The medicine is officially intended for puppies from two weeks of age and young dogs up to one year old. Adult dogs are outside the product's approved target population.

---

Contraindications and Restrictions

Classification	Population/Condition
Absolute Contraindication	Animals with a known hypersensitivity to the active ingredients (Febantel or Pyrantel) or any excipient.
Use Not Recommended	Pregnant bitches.
Use Not Intended	Breeding dogs.

The most important non-eligibility rule is the absolute contraindication against use in any animal with a history of allergic reaction to the drug’s components. Furthermore, official labeling restricts its use in breeding animals, stating it is not intended for breeding dogs and is not recommended for pregnant bitches.

Interactions with other medicines and products

The regulatory profile for Drontal Pup Oral Suspension (Febantel–Pyrantel Embonate) is structured around documented pharmacodynamic conflicts with specific classes of medicinal products. This information is derived exclusively from official government regulatory sources, such as the European Summary of Product Characteristics.

Interaction Classifications

Classification	Official Regulatory Documentation
Interaction severity classification	Contraindicated combination (for Piperazine); Risk of toxicity (for other cholinergic compounds).
Mechanistic basis of interactions	Pharmacodynamic Antagonism and Additive Pharmacodynamic Effect.

Official Interaction Statements

• Co-administration is prohibited with medicinal products containing Piperazine compounds. Regulatory documents classify this combination as subject to antagonism, which reduces the anthelmintic efficacy of the treatment.
• Caution is advised regarding the concurrent use of the product with other cholinergic compounds. This may result in an additive pharmacodynamic effect, potentially enhancing the risk of toxicity.
• The official regulatory labels do not document any specific restrictions or outcomes related to CYP enzyme metabolism, drug transporters, or the alteration of drug plasma levels (AUC/Cmax) of the active ingredients.

The interaction structure is governed by constraints on co-administration with other pharmacologically active substances, not by requirements for timing separation or restrictions related to food or supplements.

Drontal Pup utilizes a synergistic dual mechanism defined by two distinct pharmacodynamic strategies: immediate neuromuscular disruption and progressive metabolic shutdown.

Parasite Neuromuscular Blockade

This mechanism centers on Pyrantel Embonate, which acts as a cholinergic agonist by binding to Nicotinic Acetylcholine Receptors ( nAChRs) in the nematode's muscle tissue. This continuous stimulation creates a depolarizing neuromuscular blockade, leading to sustained muscle contraction and spastic paralysis. The physiological consequence is the physical detachment of the paralyzed parasite from the intestinal wall, allowing it to be subject to host peristalsis.

Inhibition of Cellular Energy Metabolism

This mechanism is driven by Febantel, a pro-drug that converts into active benzimidazole metabolites. These metabolites inhibit the polymerization of beta-Tubulin subunits, disrupting the formation of essential microtubules. The cascade blocks glucose uptake and nutrient transport, leading to critical ATP energy depletion and irreversible cellular damage. This process leads to the biological elimination of the parasite via slower, metabolic death.

How to Use Drontal Pup Oral Suspension

This section describes the administration procedure and dosing regimen for Drontal Pup.

---

Dosing and Administration Protocol

Drontal Pup is intended for oral use and is administered as a liquid suspension. The usage protocol is defined by a weight-based calculation to ensure accurate dosing of the febantel and pyrantel embonate combination.

Instruction	Description of Protocol
Dose Rate	1 mL of suspension per 1 kg body weight.
Frequency/Schedule	Treatment is initiated at 2 weeks of age and is repeated every two weeks until the time of weaning.
Preparation	The container must be thoroughly mixed by inversion before the required dose volume is withdrawn.
Dietary Context	No special dietary measures are necessary; the dose may be administered directly or mixed with feed.
Patient Population	Used in puppies from 2 weeks of age and weighing at least 0.600 kg.

---

Procedural and Usage Constraints

The usage protocol establishes conditions for administration. Prior to dose withdrawal, the suspension must be correctly prepared by inversion. The administration route and dietary flexibility allow for the dose to be given with or without food. Restrictions apply to co-administration, specifically that the suspension must not be used simultaneously with compounds containing piperazine. The prescribed schedule defines the overall treatment as a short-term, repeated course based on the animal's developmental stage.

Research Evidence / Overview of Studies for Drontal Pup

---

Evidence for Use in Treating Gastrointestinal Nematodes

The core research for the Febantel and Pyrantel Embonate combination was studied for the common intestinal parasites it is intended to address: roundworms, hookworms, and whipworms. The research includes controlled laboratory efficacy studies, often involving defined animal populations in controlled settings, as well as field trials that observe animals with naturally acquired infections in real-world environments.

Research explored the primary study outcomes, including monitoring the percentage change in the number of adult worms recovered in controlled settings. In field settings, studies monitored the Faecal Egg Count Reduction (FECR) percentage, which tracks the number of parasite eggs shed in feces during the post-treatment observation period. Findings describe patterns observed in the studies where reductions in both adult worm counts and egg shedding were observed in the populations of puppies and young dogs that was evaluated in this research. Regulatory bodies have reviewed this body of evidence in relation to the product's indication for these specific parasites.

---

Research into Exploratory Activity Against Giardia Species

Research has explored the use of the Febantel/Pyrantel combination for addressing naturally acquired giardiasis, an intestinal infection that is associated with acute or disruptive episodes. These research scenarios include Randomized Controlled Trials (RCTs) conducted during periods of increased symptom activity in dogs. Findings indicate patterns of cyst clearance and changes in fecal consistency were observed in some studies where the product was evaluated in a multi-day consecutive administration schedule.

It is important to note that the research utilized a multi-day consecutive administration schedule which differs from the single-administration schedule was studied for the labeled nematode indications. This means data are still emerging regarding efficacy in this context, and certainty remains low outside of the specifically studied multi-day regimen.

---

Long-term Follow-up and Durability of Study Outcomes

The evidence base was studied for the primary purpose of evaluating parasite clearance outcomes shortly after treatment. Therefore, the majority of the data involves research exploring short-term symptom changes and efficacy assessments at brief defined time intervals, such as one to two weeks post-treatment. There is limited information for long-term outcomes regarding the durability of the reduction in parasite burden over many months. Since the follow-up durations were limited, the research does not determine whether individuals remain parasite-free without subsequent treatment.

---

Evidence in Study Populations and Subgroups

The clinical research was highly focused on the target population of puppies and young dogs, who are particularly susceptible to these parasitic conditions. Because the research was concentrated on this target age group, data for certain groups remain insufficient. For instance, data are insufficient for canine populations outside of the specific young age group that was the primary focus of the research. Subgroup findings are uncertain when trying to apply the research patterns to canine populations outside of the specific inclusion criteria used in the registration trials.

---

Limitations and Areas of Research Uncertainty

The scientific evidence highlights what is known—and what is still uncertain—about this product. One limitation is that the follow-up durations were limited, typically only tracking outcomes for a short period after treatment, which means long-term effects are not fully established.

Furthermore, for some versions of the medicine, regulatory review may consider evidence demonstrating bioequivalence to an established reference product. In these cases, the primary evidence quality varies across studies, as direct head-to-head comparative evidence may not have been required for the specific product being evaluated. Research is ongoing in the field of parasite control, and the study results reflect the specific conditions under which they were conducted, providing context but not individual predictions.

Common questions about Drontal Pup (FAQ)

Q: Does Drontal Pup treat tapeworm?

According to the official product information, Drontal Pup is not effective against tapeworms (such as Echinococcus and Taenia). The medicine is primarily formulated for treating specific roundworms and hookworms in puppies and young dogs, but label information does not include claims for treating tapeworm infections.

Q: What is the active ingredient in Drontal Pup?

The regulatory documents state that the active ingredients in Drontal Pup are pyrantel embonate (which is equivalent to pyrantel) and febantel. These two compounds are the components responsible for treating susceptible parasitic worm infections, as indicated by regulatory documents.

Q: Can I give Drontal Pup to my dog that weighs less than 0.6 kg?

Official product information indicates that Drontal Pup is for dogs weighing at least 0.6 kg (or 0.66 kg). Regulatory documents state that instructions for use begin at or above this weight. Information regarding safe or effective use below 0.6 kg is not detailed in the official product information.

Q: What is the recommended age to start using Drontal Pup?

According to regulatory sources, treatment with Drontal Pup can begin in puppies as young as two weeks of age. The official product information specifies that two weeks of age is the earliest age for administration.

Official Storage and Disposal Requirements

Regulatory documentation defines specific storage and handling requirements for Drontal Oral Suspension for Puppies.

Condition	Regulatory Requirement
Unopened Product	Does not require any special temperature storage conditions. Shelf-life is five years.
After First Opening	Store at a temperature not exceeding 25 °C. Use the product within 12 weeks of opening.
Safety & Protection	Keep out of the sight and reach of children. Protect the product from sunlight.
Disposal	Dispose of any unused product or waste materials in accordance with local requirements. Empty containers may typically be placed in household garbage.

These mandated rules define the required environment to maintain product stability and ensure general safety, specifying different temperature controls for the unopened versus the in-use medication.